<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003255</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-968151</org_study_id>
    <secondary_id>CDR0000066143</secondary_id>
    <nct_id>NCT00003255</nct_id>
  </id_info>
  <brief_title>Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia</brief_title>
  <official_title>Phase II Study of Continuous Infusion Carboplatin and Topotecan in the Treamtment of Relapsed Acute Myelogenous Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining carboplatin and topotecan in&#xD;
      treating patients with relapsed acute myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of a 5-day continuous infusion of carboplatin and&#xD;
      topotecan in patients with relapsed and refractory acute myelogenous leukemia (AML). II.&#xD;
      Assess the toxic effects of this treatment in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive continuous intravenous infusions of topotecan and carboplatin for 5&#xD;
      days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks&#xD;
      during consolidation. No more than four courses of treatment are given. Patients are followed&#xD;
      every 6 months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>topotecan + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks during consolidation. No more than four courses of treatment are given. Patients are followed every 6 months for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>topotecan + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <arm_group_label>topotecan + carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Previously established diagnosis of acute myelogenous leukemia:&#xD;
        Failure to achieve a complete remission with initial induction regimen First relapse within&#xD;
        1 year of initial complete remission Failure to achieve complete remission with one or two&#xD;
        courses of reinduction therapy at first relapse Second relapse after no more than two&#xD;
        different induction regimens Chemotherapy-related leukemia with unfavorable cytogenetics No&#xD;
        active CNS leukemia Not eligible for allogeneic bone marrow transplant from related donor&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 74 Performance status: ECOG 0-2 Life expectancy: At&#xD;
        least 4 weeks Hematopoietic: Not specified Hepatic: Bilirubin no greater than upper limit&#xD;
        of normal (ULN) (unless elevation due to AML) Renal: Creatinine no greater than 0.3 mg/dL&#xD;
        above ULN Cardiovascular: No myocardial infarction within the past 3 months No congestive&#xD;
        heart failure No poorly controlled cardiac arrhythmia Other: Not pregnant or nursing&#xD;
        Fertile patients must use adequate contraception No psychosis No active systemic infections&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Recovered from the&#xD;
        toxic effects of previous chemotherapy At least 3 days since hydroxyurea Endocrine therapy:&#xD;
        Not specified Radiotherapy: Not specified Surgery: Not specified Other: No prior or&#xD;
        concurrent aminoglycosides or amphotericin B within past 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott H. Kaufmann, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2004</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

